

Leyre Zubiri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9205063/publications.pdf>

Version: 2024-02-01

50
papers

3,066
citations

516561

16
h-index

377752

34
g-index

51
all docs

51
docs citations

51
times ranked

6240
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. <i>American Journal of Kidney Diseases</i> , 2022, 79, 134-137.	2.1	20
2	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	0.8	75
3	Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer. <i>Cancer Cell</i> , 2022, 40, 103-108.e2.	7.7	30
4	Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy. <i>JAMA Dermatology</i> , 2022, 158, 189.	2.0	60
5	Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2022, 163, 108-118.	1.3	21
6	Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. <i>Blood Cancer Discovery</i> , 2022, 3, 181-193.	2.6	12
7	Case Report: Fulminant Celiac Disease With Combination Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 871452.	2.2	8
8	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
9	Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2507-2507.	0.8	1
10	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. <i>Oncologist</i> , 2021, 26, 49-55.	1.9	18
11	Liver biopsy findings in patients on immune checkpoint inhibitors. <i>Modern Pathology</i> , 2021, 34, 426-437.	2.9	48
12	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
13	Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2021, 1, Itab014.	1.2	10
14	Thermal Ablation, Embolization, and Selective Internal Radiation Therapy Combined with Checkpoint Inhibitor Cancer Immunotherapy: Safety Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2021, 32, 187-195.	0.2	17
15	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. , 2021, 9, e001935.		38
16	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
17	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
18	Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, e898-e901.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness.. Journal of Clinical Oncology, 2021, 39, 2655-2655.	0.8	0
20	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. Oncologist, 2021, 26, e1427-e1433.	1.9	11
21	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. Current Treatment Options in Oncology, 2021, 22, 53.	1.3	2
22	Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors. Journal of Immunotherapy and Precision Oncology, 2021, 4, 35-44.	0.6	4
23	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.. Journal of Clinical Oncology, 2021, 39, 2654-2654.	0.8	0
24	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. Oncologist, 2021, 26, 685-693.	1.9	3
25	Pericardial disease in patients treated with immune checkpoint inhibitors. , 2021, 9, e002771.		33
26	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
27	Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data. , 2021, 9, e002896.		20
28	Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction. Nephrology Dialysis Transplantation, 2021, 37, 187-189.	0.4	2
29	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
30	Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrology Dialysis Transplantation, 2021, 36, 2241-2247.	0.4	33
31	Immune checkpoint inhibitors for cancer and venous thromboembolic events. European Journal of Cancer, 2021, 158, 99-110.	1.3	35
32	814...Cutaneous immune-related adverse events are protective of mortality in patients treated with anti-PD1 and anti-PDL1 therapy in a multi-institutional cohort study. , 2021, 9, A850-A851.		0
33	804...Real-world incidence and impact of pneumonitis in lung cancer patients treated with immune checkpoint inhibitors. , 2021, 9, A841-A841.		0
34	Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 82, 743-746.	0.6	9
35	Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist, 2020, 25, e398-e404.	1.9	10
36	Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation, 2020, 142, 2299-2311.	1.6	282

#	ARTICLE	IF	CITATIONS
37	Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. <i>Kidney International Reports</i> , 2020, 5, 1700-1705.	0.4	47
38	Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. , 2020, 8, e001329.		11
39	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020, 395, 1907-1918.	6.3	1,395
40	Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Circulation</i> , 2020, 141, 2031-2034.	1.6	142
41	Diagnostic evaluation of immune checkpoint inhibitor (CPI) colitis: The role of CT scan.. <i>Journal of Clinical Oncology</i> , 2020, 38, 821-821.	0.8	0
42	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. <i>Cancer Medicine</i> , 2019, 8, 4986-4999.	1.3	27
43	The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1692-1700.	2.2	193
44	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	2.0	51
45	Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. <i>JAMA Oncology</i> , 2019, 5, 358.	3.4	48
46	Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. <i>European Journal of Endocrinology</i> , 2019, 181, 211-219.	1.9	116
47	Factors associated with severity of immune checkpoint inhibitor gastroenterocolitis requiring hospitalization in melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 81-81.	0.8	0
48	Flu vaccination rate of patients with severe immune-related adverse events.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18234-e18234.	0.8	1
49	Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6634-6634.	0.8	2
50	Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. <i>Blood</i> , 2018, 132, 1037-1037.	0.6	1